New Post Hoc Phase 3 Data Analysis Shows AJOVY® (freman

New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity

AJOVY® efficacy and safety demonstrated in migraine patients with obesity in post hoc analysis of HALO-LTS1 and FOCUS2 phase 3 studies

Obesity is a known risk factor for migraine and is...

Related Keywords

Sieria Pablo , Linda Al Hassany , Teva Pharmaceutical Industries Ltd , European Headache Congress , Teva Pharmaceutical Industries , Body Mass Index , Pharmaceutical Industries , Private Securities Litigation Reform Act , Quarterly Report , Annual Report , Post Hoc Analysis , European Headache Congress December , European Obesity Report , Gender Differences , Markets ,